1. Home
  2. STTK vs CBIO Comparison

STTK vs CBIO Comparison

Compare STTK & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

N/A

Current Price

$4.55

Market Cap

474.6M

Sector

Health Care

ML Signal

N/A

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

N/A

Current Price

$12.95

Market Cap

507.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
STTK
CBIO
Founded
2016
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
474.6M
507.1M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
STTK
CBIO
Price
$4.55
$12.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
8
Target Price
$15.40
★ $32.33
AVG Volume (30 Days)
★ 841.6K
195.3K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 53.02
N/A
EPS
★ N/A
N/A
Revenue
★ $1,000,000.00
$18,500.00
Revenue This Year
N/A
N/A
Revenue Next Year
$14.28
$37.50
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.89
$8.72
52 Week High
$8.33
$27.41

Technical Indicators

Market Signals
Indicator
STTK
CBIO
Relative Strength Index (RSI) 36.78 43.44
Support Level $4.38 $11.78
Resistance Level $7.66 $13.54
Average True Range (ATR) 0.39 1.10
MACD -0.02 -0.03
Stochastic Oscillator 14.29 20.31

Price Performance

Historical Comparison
STTK
CBIO

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: